Abstract
Purpose :
To report the visual outcomes and change in aberration profile following wavefront-optimized photorefractive keratectomy (PRK) in low, moderate and high myopic corrections.
Methods :
A retrospective chart review was performed on 60 eyes targetted for emmetropia with wavefront-optimized PRK using the ALLEGRETTO WAVE Eye-Q excimer laser (Alcon Laboratories Inc). Patients were subdivided into low (< -3.00 D, n=9), moderate (-3.00 to -6.00 D, n=30), and high myopia (> -6.00 D, n=21). Pre- and 3 to 12-month postoperative uncorrected distance visual acuity (UDVA) and wavefront aberrometry (at 5.5 mm pupil diameter) were compared.
Results :
A moderate increase in spherical aberration of 0.07 ± 0.04 μm (P=.19) and 0.11 ± 0.02 μm (P<.01) was noted for low and moderate myopic corrections, respectively, while high myopes showed a proportionally greater increase of 0.27 ± 0.05 μm (P<0.001) A decrease and mild increase was found in coma of -0.04 ± 0.05 μm (P=.67) and 0.07 ± 0.03 μm (P=.04) for mild and moderate myopia, respectively, while,high myopia achieved a greater induction of coma of 0.22 ± 0.06 μm (P<0.001) Likewise, an increase in overall higher order aberrations of 0.11 ± 05 μm (P<.001), and 0.12 ± 0.02 μm (P<0.001) were noted for mild and moderate myopia respectively, with a greater change among higher myopes at 0.33 ± 0.06 μm (P<0.001). Uncorrected visual outcomes, however were not statistically different with the level of myopia, revealing percentages of 20/15 and 20/20 to be 38% and 88% among low myopes, 69% and 90% among moderate myopes, and 48% and 71% among high myopes, respectively.
Conclusions :
Wavefront-optimized PRK with the WaveLight Allegretto Wave Eye-Q achieves excellent postoperative UDVA results, with the greatest increase in higher order aberrations (spherical aberration, coma and total higher order aberrations) among eyes with high myopia. Despite this trend of inducing a proportionately greater range of HOAs with high myopia, the visual acuities show this to not be visually significant.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.